{"id":41414,"date":"2025-09-15T16:36:24","date_gmt":"2025-09-15T08:36:24","guid":{"rendered":"https:\/\/flcube.com\/?p=41414"},"modified":"2025-09-15T16:36:24","modified_gmt":"2025-09-15T08:36:24","slug":"genrix-succeeds-with-telikibart-phase-3-targets-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41414","title":{"rendered":"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis"},"content":{"rendered":"\n<p><strong>China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/688443:SHA\">SHA: 688443<\/a>)<\/strong> announced today that its <strong>telikibart (GR1802) injection<\/strong> has successfully completed a <strong>Phase\u202f3 clinical trial<\/strong> in adults with moderate\u2011to\u2011severe atopic dermatitis (AD). The study met its primary endpoint, prompting the company to submit a marketing\u2011approval application to the <strong>Center for Drug Evaluation (CDE)<\/strong> of the National Medical Products Administration (NMPA). The CDE has already accepted the filing, marking a significant regulatory milestone for Genrix.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-is-telikibart\">What Is Telikibart?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 Telikibart is a <strong>recombinant, fully human monoclonal antibody<\/strong> that targets the <strong>IL\u20114R\u03b1<\/strong> subunit. By binding to IL\u20114R\u03b1 on the cell surface, it blocks the interaction of both IL\u20114 and IL\u201113, the key cytokines driving the Th2\u2011mediated inflammatory cascade.<\/li>\n\n\n\n<li><strong>Downstream Effects<\/strong> \u2013 Inhibition of IL\u20114\/IL\u201113 signaling prevents STAT6 phosphorylation and CD23 upregulation, thereby dampening the characteristic skin inflammation seen in AD.<\/li>\n\n\n\n<li><strong>Development Portfolio<\/strong> \u2013 Beyond AD, telikibart is in Phase\u202f3 trials for chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis; Phase\u202f2 for asthma; and Phase\u202f1b\/2 for pediatric AD.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-and-commercial-implications\">Regulatory and Commercial Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CDE Acceptance<\/strong> \u2013 The NMPA\u2019s acceptance of the application signals a clear path toward rapid market entry in China, where atopic dermatitis affects an estimated 12\u201115\u202f% of adults.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> \u2013 Telikibart offers a distinct therapeutic profile compared with existing biologics (dupilumab, tralokinumab) by targeting the shared IL\u20114R\u03b1 receptor, potentially providing broader efficacy across IL\u20114\/IL\u201113\u2011driven diseases.<\/li>\n\n\n\n<li><strong>Future Pipeline<\/strong> \u2013 Successful approval will strengthen Genrix\u2019s position in the growing dermatology biologics market and create a platform for further antibody development using its proprietary recombinant technology.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-looking-ahead\">Looking Ahead<\/h3>\n\n\n\n<p>Genrix plans to launch telikibart in the Chinese market within the next 12\u201318\u202fmonths, pending final regulatory review. The company is also exploring collaborations to expand telikibart\u2019s indications globally, leveraging its robust Phase\u202f3 data set and the expanding unmet need for targeted AD therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688443_20250912_4X7B.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688443_20250912_4X7B.\"><\/object><a id=\"wp-block-file--media-b260d046-8d11-4218-863d-43ad62128e72\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688443_20250912_4X7B.pdf\">688443_20250912_4X7B<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/688443_20250912_4X7B.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b260d046-8d11-4218-863d-43ad62128e72\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41417,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,3000,38,877],"class_list":["post-41414","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-genrix-biopharmaceutical","tag-market-approval-filings","tag-sha-688443"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection has successfully completed a Phase\u202f3 clinical trial in adults with moderate\u2011to\u2011severe atopic dermatitis (AD). The study met its primary endpoint, prompting the company to submit a marketing\u2011approval application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The CDE has already accepted the filing, marking a significant regulatory milestone for Genrix.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41414\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection has successfully completed a Phase\u202f3 clinical trial in adults with moderate\u2011to\u2011severe atopic dermatitis (AD). The study met its primary endpoint, prompting the company to submit a marketing\u2011approval application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The CDE has already accepted the filing, marking a significant regulatory milestone for Genrix.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41414\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-15T08:36:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1508.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis\",\"datePublished\":\"2025-09-15T08:36:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414\"},\"wordCount\":323,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1508.webp\",\"keywords\":[\"Auto-immune\",\"Genrix Biopharmaceutical\",\"Market approval filings\",\"SHA: 688443\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41414#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41414\",\"name\":\"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1508.webp\",\"datePublished\":\"2025-09-15T08:36:24+00:00\",\"description\":\"China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection has successfully completed a Phase\u202f3 clinical trial in adults with moderate\u2011to\u2011severe atopic dermatitis (AD). The study met its primary endpoint, prompting the company to submit a marketing\u2011approval application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The CDE has already accepted the filing, marking a significant regulatory milestone for Genrix.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41414\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1508.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1508.webp\",\"width\":1080,\"height\":608,\"caption\":\"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41414#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection has successfully completed a Phase\u202f3 clinical trial in adults with moderate\u2011to\u2011severe atopic dermatitis (AD). The study met its primary endpoint, prompting the company to submit a marketing\u2011approval application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The CDE has already accepted the filing, marking a significant regulatory milestone for Genrix.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41414","og_locale":"en_US","og_type":"article","og_title":"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis","og_description":"China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection has successfully completed a Phase\u202f3 clinical trial in adults with moderate\u2011to\u2011severe atopic dermatitis (AD). The study met its primary endpoint, prompting the company to submit a marketing\u2011approval application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The CDE has already accepted the filing, marking a significant regulatory milestone for Genrix.","og_url":"https:\/\/flcube.com\/?p=41414","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-15T08:36:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1508.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41414#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41414"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis","datePublished":"2025-09-15T08:36:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41414"},"wordCount":323,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41414#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1508.webp","keywords":["Auto-immune","Genrix Biopharmaceutical","Market approval filings","SHA: 688443"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41414#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41414","url":"https:\/\/flcube.com\/?p=41414","name":"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41414#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41414#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1508.webp","datePublished":"2025-09-15T08:36:24+00:00","description":"China\u2011based Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced today that its telikibart (GR1802) injection has successfully completed a Phase\u202f3 clinical trial in adults with moderate\u2011to\u2011severe atopic dermatitis (AD). The study met its primary endpoint, prompting the company to submit a marketing\u2011approval application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The CDE has already accepted the filing, marking a significant regulatory milestone for Genrix.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41414#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41414"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41414#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1508.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1508.webp","width":1080,"height":608,"caption":"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41414#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Genrix Succeeds with Telikibart Phase\u202f3, Targets Atopic Dermatitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1508.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41414"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41414\/revisions"}],"predecessor-version":[{"id":41418,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41414\/revisions\/41418"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41417"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}